Could a single stem cell shot ease arthritic knees?

NCT ID NCT07106229

Not yet recruiting Disease control Sponsor: Magellan Stem Cells Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 3 trial tests whether a single injection of MAG200 stem cells can improve pain and daily function in adults with knee osteoarthritis. About 573 participants will receive either a low dose, a high dose, or a placebo injection. The study aims to confirm if this approach offers a meaningful benefit over placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MAG200 (allogeneic adipose-derived mesenchymal stem cells)
What this could lead to: If it works, this could provide a new, single-injection treatment to reduce pain and improve daily function for people with knee osteoarthritis.
What could go wrong: This is a large Phase 3 trial, but stem cell treatments for osteoarthritis have had mixed results in earlier studies. The effect may be modest, and long-term safety is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRISTIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KNEE OSTEOARTHRISTIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.